Theravance Biopharma (TBPH) News Today → Shocking $16T Elon Musk Crypto Leak (From Crypto 101 Media) (Ad) Free TBPH Stock Alerts $8.77 -0.11 (-1.24%) (As of 06/7/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative June 5, 2024 | americanbankingnews.comTheravance Biopharma (NASDAQ:TBPH) Lifted to Buy at StockNews.comMay 31, 2024 | americanbankingnews.comTheravance Biopharma, Inc. to Post Q3 2024 Earnings of ($0.18) Per Share, Zacks Research Forecasts (NASDAQ:TBPH)May 28, 2024 | marketbeat.comTheravance Biopharma (NASDAQ:TBPH) Cut to Hold at StockNews.comStockNews.com cut Theravance Biopharma from a "buy" rating to a "hold" rating in a research report on Tuesday.May 24, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Guardant Health (GH), Theravance Biopharma (TBPH)May 21, 2024 | finance.yahoo.comTheravance Biopharma First Quarter 2024 Earnings: Beats ExpectationsMay 21, 2024 | marketbeat.comStockNews.com Upgrades Theravance Biopharma (NASDAQ:TBPH) to "Buy"StockNews.com raised shares of Theravance Biopharma from a "hold" rating to a "buy" rating in a research report on Monday.May 17, 2024 | markets.businessinsider.comBuy Rating Affirmed on Theravance Biopharma Amid Strong Q1 Performance and Promising Pipeline ProspectsMay 14, 2024 | markets.businessinsider.comBuy Rating Affirmed for Theravance Biopharma on Strong Portfolio Performance and Promising Drug ProspectsMay 14, 2024 | msn.comTheravance Biopharma, Inc. (NASDAQ:TBPH) Q1 2024 Earnings Call TranscriptMay 14, 2024 | marketbeat.comHC Wainwright Reaffirms Buy Rating for Theravance Biopharma (NASDAQ:TBPH)HC Wainwright restated a "buy" rating and set a $20.00 price target on shares of Theravance Biopharma in a research report on Tuesday.May 13, 2024 | investorplace.comTBPH Stock Earnings: Theravance Biopharma Beats EPS, Beats Revenue for Q1 2024May 13, 2024 | msn.comTheravance Biopharma GAAP EPS of -$0.24 beats by $0.01, revenue of $14.51M beats by $0.56MMay 13, 2024 | prnewswire.comTheravance Biopharma, Inc. Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 12, 2024 | markets.businessinsider.comTheravance Biopharma earnings preview: what Wall Street is expectingMay 12, 2024 | msn.comTheravance Biopharma Q1 2024 Earnings PreviewMay 9, 2024 | prnewswire.comTheravance Biopharma to Participate in an Upcoming Investor ConferenceMay 6, 2024 | marketbeat.comTheravance Biopharma (TBPH) to Release Earnings on MondayTheravance Biopharma (NASDAQ:TBPH) will be releasing earnings after the market closes on Monday, May 13, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=591386)April 29, 2024 | prnewswire.comTheravance Biopharma to Report First Quarter 2024 Financial Results on May 13, 2024April 17, 2024 | marketbeat.comZacks Research Analysts Reduce Earnings Estimates for Theravance Biopharma, Inc. (NASDAQ:TBPH)Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) - Stock analysts at Zacks Research lowered their FY2024 EPS estimates for shares of Theravance Biopharma in a report issued on Monday, April 15th. Zacks Research analyst K. Shah now forecasts that the biopharmaceutical company will post earniApril 17, 2024 | msn.comTheravance Biopharma (TBPH) Price Target Increased by 10.00% to 15.71April 16, 2024 | marketbeat.comTheravance Biopharma, Inc. (NASDAQ:TBPH) to Post Q1 2026 Earnings of $0.29 Per Share, Zacks Research ForecastsTheravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) - Research analysts at Zacks Research upped their Q1 2026 EPS estimates for shares of Theravance Biopharma in a research report issued on Monday, April 15th. Zacks Research analyst K. Shah now expects that the biopharmaceutical company will pApril 15, 2024 | investorplace.comBTIG Research Predicts Over 118% Rally for These 3 StocksApril 12, 2024 | marketbeat.comVanguard Group Inc. Sells 379,627 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH)Vanguard Group Inc. trimmed its holdings in Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) by 9.0% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 3,839,329 shares of the biopharmaceutical compaApril 10, 2024 | finance.yahoo.comTheravance Biopharma, Inc. to Host Virtual Key Opinion Leader (KOL) Event to Discuss Ampreloxetine's Potential for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension (nOH) in Patients with Multiple System Atrophy (MSA) on May 23, 2024April 10, 2024 | prnewswire.comTheravance Biopharma, Inc. to Host Virtual Key Opinion Leader (KOL) Event to Discuss Ampreloxetine's Potential for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension (nOH) in Patients with Multiple System Atrophy (MSA) on May 23, 2024March 26, 2024 | marketbeat.comTheravance Biopharma (NASDAQ:TBPH) Stock Price Crosses Below Fifty Day Moving Average of $9.04Theravance Biopharma (NASDAQ:TBPH) Stock Crosses Below 50 Day Moving Average of $9.04March 18, 2024 | marketbeat.comEquities Analysts Offer Predictions for Theravance Biopharma, Inc.'s Q1 2024 Earnings (NASDAQ:TBPH)Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) - Analysts at Zacks Research decreased their Q1 2024 earnings per share (EPS) estimates for shares of Theravance Biopharma in a report issued on Wednesday, March 13th. Zacks Research analyst K. Shah now anticipates that the biopharmaceuticalMarch 15, 2024 | marketbeat.comTheravance Biopharma, Inc. (NASDAQ:TBPH) Forecasted to Earn FY2026 Earnings of $0.75 Per ShareTheravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) - Research analysts at Zacks Research issued their FY2026 earnings per share estimates for shares of Theravance Biopharma in a report issued on Wednesday, March 13th. Zacks Research analyst K. Shah forecasts that the biopharmaceutical companyMarch 15, 2024 | marketbeat.comJacobs Levy Equity Management Inc. Has $3.52 Million Stock Position in Theravance Biopharma, Inc. (NASDAQ:TBPH)Jacobs Levy Equity Management Inc. lessened its holdings in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) by 31.8% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 407,525March 12, 2024 | investorplace.comShort-Squeeze Showdown: 3 Stocks Ready to Crush the SkepticsMarch 8, 2024 | marketbeat.comTheravance Biopharma, Inc. (NASDAQ:TBPH) Forecasted to Earn Q1 2024 Earnings of ($0.40) Per ShareTheravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) - Equities research analysts at Leerink Partnrs issued their Q1 2024 earnings per share estimates for shares of Theravance Biopharma in a research note issued on Tuesday, March 5th. Leerink Partnrs analyst D. Risinger anticipates that the bioMarch 7, 2024 | markets.businessinsider.comAnalyst Reiterates Buy Rating with Increased Price Target Amidst Financial Adjustments and Milestone Payment PotentialMarch 7, 2024 | marketbeat.comFY2026 EPS Estimates for Theravance Biopharma, Inc. Raised by Leerink Partnrs (NASDAQ:TBPH)Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) - Equities research analysts at Leerink Partnrs lifted their FY2026 earnings per share estimates for Theravance Biopharma in a research note issued on Tuesday, March 5th. Leerink Partnrs analyst D. Risinger now forecasts that the biopharmaceuFebruary 28, 2024 | markets.businessinsider.comTheravance Biopharma: A Strong Buy on Underappreciated Cash Flow Potential and Strategic MilestonesFebruary 28, 2024 | finance.yahoo.comTheravance Biopharma, Inc. (NASDAQ:TBPH) Q4 2023 Earnings Call TranscriptFebruary 27, 2024 | stockhouse.comTheravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateFebruary 27, 2024 | investing.comTheravance Biopharma Inc (TBPH)February 27, 2024 | markets.businessinsider.comBalancing Growth Prospects and Clinical Outcomes: Hold Rating on Theravance BiopharmaFebruary 26, 2024 | msn.comTheravance Biopharma GAAP EPS of -$0.17 misses by $0.02, revenue of $17.6M beats by $0.03MFebruary 26, 2024 | prnewswire.comTheravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateFebruary 25, 2024 | seekingalpha.comTheravance Biopharma Q4 2023 Earnings PreviewFebruary 24, 2024 | benzinga.comTheravance Biopharma Stock (NASDAQ:TBPH) Dividends: History, Yield and DatesFebruary 24, 2024 | msn.comTheravance Biopharma (TBPH) Price Target Increased by 5.77% to 14.03February 22, 2024 | prnewswire.comTheravance Biopharma to Participate in an Upcoming Investor ConferenceFebruary 15, 2024 | finance.yahoo.comWill Theravance Biopharma (NASDAQ:TBPH) Spend Its Cash Wisely?February 15, 2024 | marketbeat.comTheravance Biopharma (NASDAQ:TBPH) Stock Price Passes Below 200-Day Moving Average of $9.83Theravance Biopharma (NASDAQ:TBPH) Share Price Passes Below Two Hundred Day Moving Average of $9.83February 14, 2024 | finance.yahoo.comTheravance Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024February 14, 2024 | prnewswire.comTheravance Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024February 1, 2024 | finance.yahoo.comTheravance Biopharma, Inc. (TBPH)January 29, 2024 | marketbeat.comFY2024 EPS Estimates for Theravance Biopharma, Inc. Lifted by Zacks Research (NASDAQ:TBPH)Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) - Research analysts at Zacks Research raised their FY2024 EPS estimates for Theravance Biopharma in a report issued on Thursday, January 25th. Zacks Research analyst K. Shah now forecasts that the biopharmaceutical company will post earnings Get Theravance Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for TBPH and its competitors with MarketBeat's FREE daily newsletter. Email Address 3 Dirt-Cheap Stocks You Can’t Afford to Ignore (Ad)Often, investors will overlook stocks just because they're cheap. It's a common thought that a cheap price tag means that something must be wrong with the company. But this couldn't be further from the case in many instances. Get your FREE look at these THREE companies right here. TBPH Media Mentions By Week TBPH Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TBPH News Sentiment▼-0.500.76▲Average Medical News Sentiment TBPH News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TBPH Articles This Week▼12▲TBPH Articles Average Week Get Theravance Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for TBPH and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ANNX News PLRX News EWTX News TARO News SNDX News ARDX News KURA News DVAX News SDGR News SUPN News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TBPH) was last updated on 6/9/2024 by MarketBeat.com Staff From Our PartnersTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredBiden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend in...The Freeport Society | SponsoredRSVP: Charles Payne’s Cash Flow WorkshopDid you know you could "cash flow" the stocks in your portfolio? Without selling a single share of stock? ...Unstoppable Prosperity | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredMoonshot Coins for the Current Crypto RunDid you see bitcoin crossed $70k again? Don't miss the next bull run. Because while Bitcoin and Ethereum s...Crypto 101 Media | Sponsored